Tag:

multiple sclerosis

Latest Headlines

Latest Headlines

Biogen taps Google's data analytics skills for MS research

The Google X lab that spawned smart contact lenses and self-driving cars is teaming up with Biogen Idec to unravel patient-to-patient variation in the progression of multiple sclerosis.

Google, Biogen team up on MS research: report

Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec will team up with Google to sift through a mountain of data on the topic, according to a report from Bloomberg.

UPDATED: Biogen Idec's remyelination drug raises hopes--and fears--in PhII

Shares of Biogen Idec were buoyed this morning after the big biotech highlighted positive data from its mid-stage study of anti-LINGO-1, a closely watched drug that raises the potential for spurring remyelination--repairing the damage done by diseases like multiple sclerosis. But a careful second look at the results also underscores just how challenging this development program is for Biogen Idec.

The bright side to Sanofi's Lemtrada delay? Its support-to-sell marketing plan

Sanofi's Genzyme has found a silver lining to last winter's FDA snub of Lemtrada. For starters, Genzyme is fielding an extensive provider-and-patient support program, developed based on feedback from a range of stakeholders.

MIT spinoff Microchips finishes development of its birth control, osteoporosis implant

Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.

PhIII failure dashes Novartis' hopes of Gilenya label expansion

Novartis is looking to expand sales of oral multiple sclerosis therapy Gilenya, which currently trails Biogen Idec pill Tecfidera in the MS arena despite its first-to-market advantage. But it looks like it won't be doing that with a primary progressive MS indication anytime soon.

GeNeuro snags a $455M deal, inks MS drug pact with Servier

Geneva-based GeNeuro, a spinout of the Institut Mérieux, has come up with a licensing deal that will deliver $47 million needed to complete a Phase IIb study of its experimental therapy for multiple sclerosis. And France's Servier gets an option on ex-U.S. and Japanese rights that's tied to a $408 million package of milestones along with a chance to buy an equity stake in the biotech sometime in the next year.

Autoimmune experts discover a new pathway for multiple sclerosis R&D

Blocking the cascade of events that trigger autoimmune disease is a key focus in multiple sclerosis research. And a multidisciplinary team of investigators in Singapore says they have figured out one piece of the puzzle that could offer a new discovery pathway for the disease.

FDA reverses an embarrassing rejection of Sanofi's Lemtrada, OKs MS drug

Late on Friday the FDA put out the word that it has reversed its earlier decision against Sanofi's multiple sclerosis drug Lemtrada, agreeing to allow the pharma giant the right to market the treatment--with some tight controls on just who will get this drug for the relapsing form of the disease.

Novartis breaks out in song with MS campaign featuring David Osmond

Novartis has added a bit of pop to its already extensive Gilenya marketing. Not content with a Twitter feed, a YouTube channel, a self-management smartphone app, and a gaggle of awareness pushes, the Swiss drugmaker is now in the music business.